Jacquelot Nicolas, Pitt Jonathan M, Enot David P, Roberti Maria Paula, Duong Connie P M, Rusakiewicz Sylvie, Eggermont Alexander M, Zitvogel Laurence
Gustave Roussy, Université Paris-Saclay, INSERM U1015, Villejuif, F-94805, France.
Gustave Roussy, Université Paris-saclay, Metabolomics and Cell Biology Platforms, Villejuif, F-94805, France.
Oncoimmunology. 2017 Mar 7;6(8):e1299303. doi: 10.1080/2162402X.2017.1299303. eCollection 2017.
Existing clinical, anatomopathological and molecular biomarkers fail to reliably predict the prognosis of cutaneous melanoma. Biomarkers for determining which patients receive adjuvant therapies are needed. The emergence of new technologies and the discovery of new immune populations with different prognostic values allow the immune network in the tumor to be better understood. Importantly, new molecules identified and expressed by immune cells have been shown to reduce the antitumor immune efficacy of therapies, prompting researchers to develop antibodies targeting these so-called "immune checkpoints", which have now entered the oncotherapeutic armamentarium.
现有的临床、解剖病理学和分子生物标志物无法可靠地预测皮肤黑色素瘤的预后。因此需要能够确定哪些患者适合接受辅助治疗的生物标志物。新技术的出现以及具有不同预后价值的新免疫群体的发现，使人们能够更好地了解肿瘤中的免疫网络。重要的是，免疫细胞识别并表达的新分子已被证明会降低治疗的抗肿瘤免疫疗效，促使研究人员开发针对这些所谓“免疫检查点”的抗体，这些抗体现已进入肿瘤治疗药物库。
